Secondary Logo

Journal Logo

Cyclosporine Lowering With Everolimus or Mycophenolate to Preserve Renal Function in Heart Recipients: A Randomized Study

Potena, Luciano; Bianchi, Isidoro G.; Magnani, Gaia; Masetti, Marco; Coccolo, Fabio; Fallani, Francesco; Russo, Antonio; Grigioni, Francesco; Branzi, Angelo; Ponticelli, Claudio

doi: 10.1097/TP.0b013e3181c42b95
Letters to the Editor
Free
SDC

Cardiovascular Department; University of Bologna; Bologna, Italy (Potena, Bianchi, Magnani, Masetti, Coccolo, Fallani, Russo, Grigioni, Branzi)

Division of Nephrology; IRCCS Humanitas; Milan, Italy (Ponticelli)

This work was supported by Cardiovascular Department of The University of Bologna and by Banca del Monte Foundation.

L. Potena received consultancy/advisory board fees from Novartis Pharma, Italy, Roche s.p.a,. Italy, and CSL Behring; C. Ponticelli is a consultant of Novartis Pharma, Italy and received fees from Virapharma; drug manufacturers did not participate in any phase of the study design, analysis or reporting.

L. Potena conceived and designed the study, participated in data analysis, and wrote the manuscript; I.G. Bianchi participated in research performance and data collection and analysis and reviewed the manuscript; C. Ponticelli participated in study design and reviewed the manuscript; G. Magnani participated in research performance and reviewed the manuscript; M. Masetti participated in study design, research performance, and data collection; F. Coccolo participated in research performance and data collection and analysis and reviewed the manuscript; F. Fallani participated in research performance and data collection and analysis and reviewed the manuscript; A. Russo participated in research performance and reviewed the manuscript; F. Grigioni participated in study design, research performance, and manuscript writing; A. Branzi directed the research group, participated in study design, and reviewed the manuscript.

Address correspondence to: Luciano Potena, M.D., Ph.D., Dipartimento Cardiovascolare, Policlinico S.Orsola-Malpighi, Pad. 21, Via Massarenti, 9, 40138 Bologna, Italy.

E-mail: luciano.potena2@unibo.it

Received 4 September 2009.

Accepted 16 September 2009.

Calcineurin inhibitors (CNIs) represent the cornerstone of immunosuppressive therapy in heart transplant (HT) recipients. CNI nephrotoxicity, however, may cause irreversible renal failure, which is a major mortality risk factor (1–4). To reduce these risks, successful attempts to minimize or avoid CNI by introducing newer immunosuppressants, such as mycophenolate mofetil (MMF) and mammalian target of rapamycin (mTOR) inhibitors, have been reported (5–15). However, randomized studies comparing the safety and efficacy profile of CNI reduction under the umbrella of MMF or an mTOR inhibitor are lacking.

Back to Top | Article Outline

METHODS

This single-center randomized controlled study in stable HT recipients (registered at clinicaltrials.org, NCT00420537) was designed, conducted, and analyzed independently of the study drug manufacturers. The study objective was to demonstrate the possibility of limiting renal disease progression by reducing cyclosporine doses (Sandimunn Neoral, Novartis Pharma, Basel, CH) while adding MMF (Cellcept, Roche, Basel, CH) or the mTOR inhibitor everolimus (Certican, Novartis Pharma).

Inclusion criteria comprised time from transplant between 1 and 4 years and calculated creatinine clearance (CrCl) between 20 and 60 mL/min (16). Study protocol was approved by the local ethical committee.

After a baseline clinical and laboratory evaluation, patients were randomly assigned to receive either everolimus adjusted to 3 to 8 ng/mL blood trough levels (C0) and cyclosporine adjusted to 40 to 90 ng/mL C0 or MMF 1.5 g twice daily and cyclosporine adjusted to 100 to 150 ng/mL C0. Everolimus was started at 0.25 mg twice daily with concomitant 25% to 30% cyclosporine dose reduction and MMF or azathioprine withdrawal. After 5 to 7 days, white cell count and drugs C0 were checked, with further doses adjustment if needed.

Allocation was balanced by the minimization method (17) for presence of baseline CrCl more than or equal to 40 mL/min, diabetes, and pretransplant coronary artery disease.

The primary endpoint was the difference in CrCl between the two study groups. Assuming a 22% coefficient of variability of mean CrCl, a sample of 70 patients was needed to provide 80% power to detect a difference of 15% in CrCl between the study arms 12 months after randomization. Secondary endpoints were change of CrCl within and across the study arms, clinical and laboratory predictors of CrCl change, incidence of biopsy-proven acute rejection, and incidence of infection requiring specific antimicrobial treatment.

Back to Top | Article Outline

RESULTS

Thirty-four patients, transplanted 2.5±1.3 years before with baseline CrCl of 43.5±9.1 mL/min, were allocated to either everolimus (n=17) or MMF (n=17) arm. Six to 8 months before baseline, CrCl was 47.1±11.5 mL/min, indicating a progressive loss of renal function before study interventions (P=0.02 vs. baseline). Pulmonary infections caused one death in the MMF arm and one drug discontinuation in everolimus arm. Study enrollment was halted when only half of the planned population entered the study because of safety issues raised after 6 months of follow-up by 5 (29%) patients developing bacterial infections in the everolimus arm versus only one (6%) on MMF (P=0.04). However, at the end of study period, the estimated incidence of infection was similar in both arms (29±11 vs. 24±10%; P=0.5).

Mean cyclosporine levels lowered by 65% in the everolimus arm (from 175±75 ng/mL to 60±32 ng/mL) and by 31% in the MMF arm (from 198±55 ng/mL to 136±34 ng/mL). After cyclosporine reduction, overall CrCl improved during the first 2 months (47.2±13.6 mL/min; P=0.03) and then stabilized toward the end of the study period (47.1±13.8 mL/min; P=0.1; all P values calculated for paired analysis). Both study interventions halted prestudy decline in CrCl, with no significant difference in CrCl at month 12 (49.8±13.4 vs. 44.5±13.8 mL/min; P=0.5; Fig. 1), suggesting overall efficacy of study interventions in reducing the progression of renal dysfunction.

FIGURE 1.

FIGURE 1.

A baseline proteinuria less than 150 mg/24 hr was the only independent predictor of CrCl improvement during the study period (odds ratio [95% confidence interval]=5.5 [1.05– 29.4], P=0.04). To explore the interaction of proteinuria with study interventions, we stratified the paired comparisons between baseline and month 12 CrCl within study arms. Proteinuria less than 150 mg/24 hr was significantly associated with CrCl improvement in the everolimus group (from 45.8±7.7 to 50.5±8.6; P=0.02) and with borderline significant CrCl improvement in the MMF arm (from 42.7± 6.9 mL/min to 47.9±8.1 mL/min; P=0.06). Conversely, proteinuria more than or equal to 150 mg/24 hr identified everolimus patients with numerically worsening renal function (Fig. 1).

At study entry, 31 (91%) patients were on statin therapy. Although we found no significant difference in final low-density lipoproteins levels between study arms (104±38 mg/dL vs. 91±31 mg/dL; P=0.3), five patients on everolimus required an increase in statin dose. Moreover, everolimus intake was associated with a significant increase in triglycerides concentration (142±77 mg/dL vs. 204±95 mg/dL; P=0.01 for paired analysis).

Back to Top | Article Outline

DISCUSSION

This randomized study shows the possibility of halting the progression of renal dysfunction in midterm HT recipients through the introduction of everolimus or MMF and concomitant cyclosporine reduction. Despite a greater cyclosporine reduction in everolimus patients, at the end of the study, CrCl was similar between study groups. In addition, exploratory analyses suggest that an even minor proteinuria can identify HT recipients unlikely to respond to mTOR conversion, as already reported in kidney and lung transplant recipients (18–20).

Study enrollment was interrupted because an increased number of bacterial infections during the initial period after everolimus start. However, infectious episodes were later balanced in the MMF arm with no final difference between the groups. On the basis of this experience, we believe that the use of low-dose antibacterial prophylaxis for urinary and lung infection and a strict clinical monitoring during the first months after everolimus introduction may be appropriate.

The major limitation of this study is the reduced sample size that did not make it possible to reach the planned power to detect differences in renal function in the study groups. Thus, most of the findings should be considered only hypothesis-generating because deriving from secondary endpoint analysis. However, to our knowledge, this is the first randomized study testing cyclosporine reduction with everolimus or MMF for progression of CNI-dependent renal dysfunction in HT recipients, and we believe that it may provide some clinical hints in the choice for the optimal kidney sparing strategy. Indeed, within analogous overall efficacy of both treatments in reducing CNI nephrotoxicity, MMF showed a smoother safety profile than everolimus. Conversely, lack of proteinuria may help to select optimal candidates to everolimus-based CNI minimization, who may also take advantage of the potential benefits of everolimus antiproliferative properties (21–23).

Back to Top | Article Outline

ACKNOWLEDGMENT

The authors thank the nursing team of the Bologna Heart Transplant Center for the help in sample collections and study visits organization.

Luciano Potena

Isidoro G. Bianchi

Gaia Magnani

Marco Masetti

Fabio Coccolo

Francesco Fallani

Antonio Russo

Francesco Grigioni

Angelo Branzi

Cardiovascular Department

University of Bologna

Bologna, Italy

Claudio Ponticelli

Division of Nephrology

IRCCS Humanitas

Milan, Italy

Back to Top | Article Outline

REFERENCES

1.Zuckermann AO, Aliabadi AZ. Calcineurin-inhibitor minimization protocols in heart transplantation. Transpl Int 2009; 22: 78.
2.Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: Focus on improving renal function and nephrotoxicity. Clin Transplant 2008; 22: 1.
3.Bloom RD, Doyle AM. Kidney disease after heart and lung transplantation. Am J Transplant 2006; 6: 671.
4.Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931.
5.Al-Aly Z, Sachdeva A, Philoctete Ashley JM, et al. Preliminary experience with mycophenolate mofetil for preservation of renal function in cardiac transplant patients with documented cyclosporine nephrotoxicity. Nephrology (Carlton) 2006; 11: 151.
6.Manito N, Kaplinsky EJ, Roca J, et al. Heart transplant recipient clinical profile improvement following mycophenolate mofetil late incorporation into the treatment schedule. Clin Transplant 2005; 19: 304.
7.Sanchez V, Delgado JF, Morales JM, et al. Chronic cyclosporine-induced nephrotoxiciy in heart transplant patients: Long-term benefits of treatment with mycophenolate mofetil and low-dose cyclosporine. Transplant Proc 2004; 36: 2823.
8.Baryalei M, Zenker D, Pieske B, et al. Renal function and safety of heart transplant recipients switched to mycophenolate mofetil and low-dose cyclosporine. Transplant Proc 2003; 35: 1539.
9.Tedoriya T, Keogh AM, Kusano K, et al. Reversal of chronic cyclosporine nephrotoxicity after heart transplantation-potential role of mycophenolate mofetil. J Heart Lung Transplant 2002; 21: 976.
10.Aleksic I, Baryalei M, Busch T, et al. Improvement of impaired renal function in heart transplant recipients treated with mycophenolate mofetil and low-dose cyclosporine. Transplantation 2000; 69: 1586.
11.Angermann CE, Stork S, Costard-Jackle A, et al. Reduction of cyclosporine after introduction of mycophenolate mofetil improves chronic renal dysfunction in heart transplant recipients—The IMPROVED multi-centre study. Eur Heart J 2004; 25: 1626.
12.Ross H, Pflugfelder P, Haddad H, et al. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients. J Heart Lung Transplant 2008; 27: 197.
13.Schweiger M, Wasler A, Prenner G, et al. Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients. Transpl Immunol 2006; 16: 46.
14.Balfour IC, Srun SW, Wood EG, et al. Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients. J Heart Lung Transplant 2006; 25: 518.
15.Trosch F, Rothenburger M, Schneider M, et al. First experience with rapamycin-based immunosuppression to improve kidney function after heart transplantation. Thorac Cardiovasc Surg 2004; 52: 163.
16.Cockcroft D, Gault M. Prediction of creatinine clearance from serum creatinine. Nephron 1975; 16: 31.
17.Scott NW, McPherson GC, Ramsay CR, et al. The method of minimization for allocation to clinical trials. A review. Control Clin Trials 2002; 23: 662.
18.Diekmann F, Budde K, Slowinski T, et al. Conversion to sirolimus for chronic allograft dysfunction: Long-term results confirm predictive value of proteinuria. Transpl Int 2008; 21: 152.
19.Stephany BR, Boumitri M, Budev M, et al. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease. J Heart Lung Transplant 2009; 28: 564.
20.Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233.
21.Potena L, Fearon WF, Sydow K, et al. Asymmetric dimethylarginine and cardiac allograft vasculopathy progression: Modulation by sirolimus. Transplantation 2008; 85: 827.
22.Andrassy J, Graeb C, Rentsch M, et al. mTOR inhibition and its effect on cancer in transplantation. Transplantation 2005; 80(1 suppl): S171.
23.Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003; 108: 48.
© 2010 Lippincott Williams & Wilkins, Inc.